Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report)'s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.33 and traded as high as $1.53. Microbot Medical shares last traded at $1.49, with a volume of 374,393 shares.
Wall Street Analyst Weigh In
Separately, HC Wainwright increased their price objective on shares of Microbot Medical from $7.00 to $9.00 and gave the company a "buy" rating in a research report on Friday, January 24th.
Read Our Latest Research Report on Microbot Medical
Microbot Medical Price Performance
The company has a market capitalization of $51.77 million, a price-to-earnings ratio of -1.86 and a beta of 1.40. The stock has a 50 day simple moving average of $1.71 and a two-hundred day simple moving average of $1.34.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings data on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). Equities research analysts predict that Microbot Medical Inc. will post -0.71 EPS for the current year.
Hedge Funds Weigh In On Microbot Medical
A hedge fund recently bought a new stake in Microbot Medical stock. Renaissance Technologies LLC bought a new position in Microbot Medical Inc. (NASDAQ:MBOT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 105,658 shares of the biotechnology company's stock, valued at approximately $118,000. Renaissance Technologies LLC owned 0.52% of Microbot Medical as of its most recent filing with the Securities and Exchange Commission. 16.30% of the stock is currently owned by institutional investors and hedge funds.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
See Also
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
